Therapy for lysosomal enzyme deficiencies

Details Therapy for lysosomal enzyme deficiencies Therapy for lysosomal enzyme deficiencies

2011-08-30

2011-08-30

Tate, Christopher R (Department: 1655)

Drug, bio-affecting and body treating compositions

Extract or material containing or obtained from a...

C424S400000

Reexamination Certificate

active

08007814

ABSTRACT:
The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.

REFERENCES:
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 4160452 (1979-07-01), Theeuwes
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4384975 (1983-05-01), Fong
patent: 4389330 (1983-06-01), Tice et al.
patent: 4652441 (1987-03-01), Okada et al.
patent: 4663308 (1987-05-01), Saffran et al.
patent: 4777049 (1988-10-01), Magruder et al.
patent: 4810646 (1989-03-01), Jamas et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4956778 (1990-09-01), Naito
patent: 4992540 (1991-02-01), Jamas et al.
patent: 5028703 (1991-07-01), Jamas et al.
patent: 5032401 (1991-07-01), Jamas et al.
patent: 5082936 (1992-01-01), Jamas et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5322841 (1994-06-01), Jamas et al.
patent: 5401727 (1995-03-01), Rorstad et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5488040 (1996-01-01), Jamas et al.
patent: 5504079 (1996-04-01), Jamas et al.
patent: 5532223 (1996-07-01), Jamas et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5607677 (1997-03-01), Jamas et al.
patent: 5622939 (1997-04-01), Jamas et al.
patent: 5622940 (1997-04-01), Ostroff
patent: 5633369 (1997-05-01), Jamas et al.
patent: 5663324 (1997-09-01), James et al.
patent: 5705153 (1998-01-01), Shorr et al.
patent: 5741495 (1998-04-01), Jamas et al.
patent: 5783569 (1998-07-01), Jamas et al.
patent: 5811542 (1998-09-01), Jamas et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5817643 (1998-10-01), Jamas et al.
patent: 5849720 (1998-12-01), Jamas et al.
patent: 5879680 (1999-03-01), Ginns et al.
patent: 5911983 (1999-06-01), Barranger et al.
patent: 5968811 (1999-10-01), Greenshields
patent: 6074864 (2000-06-01), Ginns et al.
patent: 6118045 (2000-09-01), Reuser et al.
patent: 6133229 (2000-10-01), Gibson et al.
patent: 6369216 (2002-04-01), Patchen et al.
patent: 6372499 (2002-04-01), Midoux et al.
patent: 6379965 (2002-04-01), Boutin
patent: 6420176 (2002-07-01), Lisziewicz et al.
patent: 6444448 (2002-09-01), Wheatcroft et al.
patent: 6476003 (2002-11-01), Jordan et al.
patent: 6495570 (2002-12-01), Jacob et al.
patent: 6512097 (2003-01-01), Marks et al.
patent: 6696272 (2004-02-01), Mahuran et al.
patent: 7022685 (2006-04-01), Patchen et al.
patent: 7220427 (2007-05-01), Jordan
patent: 7229623 (2007-06-01), Cheever et al.
patent: 2002/0032170 (2002-03-01), Jamas et al.
patent: 2002/0143174 (2002-10-01), Patchen et al.
patent: 2003/0216346 (2003-11-01), Sakurai et al.
patent: 2004/0014715 (2004-01-01), Ostroff
patent: 2004/0116380 (2004-06-01), Jamas et al.
patent: 2005/0245480 (2005-11-01), Ostroff et al.
patent: 2005/0281781 (2005-12-01), Ostroff
patent: 2006/0165700 (2006-07-01), Ostroff et al.
patent: 2006/0247205 (2006-11-01), Patchen et al.
patent: 2008/0044438 (2008-02-01), Ostroff et al.
patent: 2008/0220038 (2008-09-01), Franklin et al.
patent: 0242135 (1987-10-01), None
patent: WO 89/05850 (1989-06-01), None
patent: 90/15596 (1990-12-01), None
patent: 91/03248 (1991-03-01), None
patent: 91/03495 (1991-03-01), None
patent: 92/07064 (1992-04-01), None
patent: 94/04163 (1994-03-01), None
patent: 00/18411 (2000-04-01), None
patent: WO 02/12348 (2002-02-01), None
patent: 2004/014320 (2004-02-01), None
patent: WO 2004/012657 (2004-02-01), None
patent: WO 2004/021994 (2004-03-01), None
patent: 2004/037232 (2004-05-01), None
patent: 2005/014776 (2005-02-01), None
patent: WO 2006/007372 (2006-01-01), None
patent: 2006/032039 (2006-03-01), None
patent: 2007/050643 (2007-05-01), None
patent: 2007/109564 (2007-09-01), None
patent: 2009/058913 (2009-05-01), None
Fabrega, S., et al., “Human Glucocerebrosidase: Heterologous Expression of Active Site Mutants in Murine Null Cells”,Glycobiology, Vo. 10, No. 11, pp. 1217-1224, 2000.
pIRES-EGFP, Vector Information, GenBank Accession #: Submission in Progress, PT3157-5, Clontech Laboratories, Inc., 1997.
Hiraiwa, M., et al., “Isolation, Characterization, and Proteolysis of Human Prosaposin, the Precursor of Saposins (Sphingolipid Activator Proteins)”,Archives of Biochemistry and Biophysics, vol. 304, No. 1, July, pp. 110-116, 1993.
NIH Guide: CNS Therapy Development for Lysosomal Storage Disorders, Department of Health and Human Services, Release Date: Jul. 2, 2004, PA No. PAS-04-120.
Aviner, S., et al., Case Report “Anaphylactoid Reaction to Imiglucerase, but Not to Alglucerase, in a Type I Gaucher Patient”,Blood Cells, Molecules, and Diseases(1999), 25(5), Mar. 15: pp. 92-94.
Orvisky, E., et al., “Glucosylsphingosine Accumulation in Tissues from Patients with Gaucher Disease: Correlation with Phenotype and Genotype”,Molecular Genetics and Metabolism76 (2002), pp. 262-270.
Erickson, A., et al., “Biosynthesis of the Lysosomal Enzyme Glucocerebrosidase”,The Journal of Biological Chemistry, vol. 260, No. 26, Nov. 15, pp. 14319-14324.
Bonten, E. J., et al., “Targeting Macrophages with Baculovirus-Produced Lysosomal Enzymes: Implications for Enzyme Replacement Therapy of the Glycoprotein Storage Disorder Galactosialidosis”,The FASEB Journal, Express Article 10.1096/fj. 03-0941 fje., Published online Apr. 14, 2004.
Reichner, J. S., et al., “Receptor-Mediated Phagocytosis of Rat Macrophages is Regulated Differentially for Opsonized Particles and Non-Opsonized Particles Containing β-glucan”,Immunology, 2001, 104, pp. 198-206.
Wilcox, W. R., MD, PhD, “Lysosomal Storage Disorders: The Need for Better Pediatric Recognition and Comprehensive Care”,The Journal of Pediatrics, May 2004, pp. S3-S14.
Wilson, H.M., et al., “Targeting Genetically Modified Macrophages to the Glomerulus”,Nephron Experimental Nephrology, Minireview, 2003, 94:e 113-e 118.
Eto, Y., et al., “Treatment of Lysosomal Storage Disorders: Cell Therapy and Gene Therapy”,J. Inherit. Metab. Dis.27 (2004), pp. 411-415.
Ribeiro, C.C., et al., “Calcium Phosphate-Alginate Microspheres as Enzyme Delivery Matrices”,Biomaterials25 (2004), pp. 4363-4373.
Germain, D. P., et al., “Fabry Disease: Recent Advances in Enzyme Replacement Therapy”,Expert Opinion, Investig. Drugs(2002), pp. 1467-1476.
Cho, M. E., et al., “Fabry Disease in the Era of Enzyme Replacement Therapy: a Renal Perspective”,Pediatr Nephrol(2004) 19:583-593.
LeBowitz, J. H., et al., “Glycosylation-Independent Targeting Enhances Delivery to Lysosomes and Decreases Storage in Mucopolysaccharidosis Type VII Mice”,PNAS, Mar. 2, 2004, vol. 101, No. 9, pp. 3083-3088.
Sleeper, M. M., VMD et al., “Gene Therapy Ameliorates Cardiovascular Disease in Dogs with Mucopolysaccharidosis VII”,Circulation, Aug. 17, 2004, pp. 815-820.
Burke, B., et al., “Macrophages in Gene Therapy: Cellular Delivery Vehicles and in Vivo Targets”,Journal of Leukocyte Biology, vol. 72, Sep. 2002, pp. 417-428.
Burke, B., “Macrophages as Novel Cellular Vehicles for Gene Therapy”,Expert Opinion, Biol Ther.(2003) 3(6), pp. 919-924.
Novelli, E. M., et al., “Gene Therapy for Lysosomal Storage Disorders”,Expert Opinion, Biol Ther.(2001) 1(5), pp. 857-867.
Grabowski, G.A., MD, “Gaucher Disease: Lessons From a Decade of Therapy”,The Journal of Pediatrics, May 2004, S15-S19.
Desnick, R. J., PhD, MD, et al., “Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replaceme

Affiliated with

Also associated with

Rating

Therapy for lysosomal enzyme deficiencies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapy for lysosomal enzyme deficiencies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy for lysosomal enzyme deficiencies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2773570